SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Vineet Laboratories - Quaterly Results

22 Jul 2025 Evaluate
The sales slipped to Rs. 74.42 millions, down -68.81% for the June 2025 quarter as against Rs. 238.62 millions during the year-ago period.The Net Loss for the quarter ended June 2025 is Rs. -8.65 millions as compared to Net Loss of Rs. -21.32 millions of corresponding quarter ended June 2024 Operating profit Margin for the quarter ended June 2025 improved to 3.36% as compared to -4.23% of corresponding quarter ended June 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 74.42 238.62 -68.81 74.42 238.62 -68.81 749.95 1505.91 -50.20
Other Income 0.18 3.73 -95.17 0.18 3.73 -95.17 19.87 4.63 329.16
PBIDT 3.36 -4.23 -179.43 3.36 -4.23 -179.43 -142.96 76.63 -286.56
Interest 6.12 11.37 -46.17 6.12 11.37 -46.17 39.78 47.81 -16.80
PBDT -2.76 -15.60 -82.31 -2.76 -15.60 -82.31 -182.74 28.82 -734.07
Depreciation 6.25 6.09 2.63 6.25 6.09 2.63 25.02 25.19 -0.67
PBT -9.01 -21.69 -58.46 -9.01 -21.69 -58.46 -207.76 3.63 -5823.42
TAX -0.36 -0.37 -2.70 -0.36 -0.37 -2.70 -5.85 -6.64 -11.90
Deferred Tax -0.36 -0.37 -2.70 -0.36 -0.37 -2.70 -5.85 -5.99 -2.34
PAT -8.65 -21.32 -59.43 -8.65 -21.32 -59.43 -201.91 10.27 -2066.02
Equity 92.19 92.19 0.00 92.19 92.19 0.00 92.19 92.19 0.00
PBIDTM(%) 4.51 -1.77 -354.69 4.51 -1.77 -354.69 -19.06 5.09 -474.61

Vineet Laboratories Share Price

39.50 -0.19 (-0.48%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×